2021: A year in Review

23 Dec 2021

  Light blue, shaggy looking flower

When I joined Double Rainbow, I knew I was joining a team of brilliant scientists, but looking back on my first year with the organization I am still in awe of what they have accomplished. Founded in 2017, the original team of eight has worked tirelessly to bring two groundbreaking drug discovery platforms to life. What started as an idea between our two co-founders has blossomed into a rapidly growing biotech, now poised to bring its first wave of discovery compounds into preclinical development.

Looking back at 2021, our team has made tremendous progress in our ambition to deliver a new therapeutic modality to patients around the world. From starting the year with the original core team of scientists to ending it with more than 20 employees, this year has been one defined by growth and lead by our aspiration to reimagine what it means to be well.

There have been many milestones along the way, but a few that stand out are:

As we look forward to 2022, we are so thankful for the team members that have helped us to this point. They have tackled a rapidly evolving environment and advanced our science in ways previously only imagined. I have no doubt that they are ready to tackle whatever comes next, and that our greatest moments are yet to come.

A portrait of   Cavan Farley

Written By Cavan Farley

Cavan Farley is Vice-President, Global Business Groups at Double Rainbow. An award-winning senior executive, Cavan has held critical roles across multiple business channels, including market access, sales and marketing, and planning and execution.

Related News